Results of a recent clinical study using a fully automated, standardised thrombin generation analyser have shown that it is possible to identify breast cancer patients who are at high risk of disease recurrence.
A diagnosis of cancer increases the risk of venous thromboembolism (VTE) for all patients, accounting for up to 20% of cases,1 with thrombosis the second leading cause of death after the disease itself.2,3
Breast cancer is the most common malignant disease worldwide, with women facing a three- to four-fold increased risk of VTE compared to those of the same age without the disease.4 Cancer-associated hypercoagulability is also linked to a greater chance of early disease recurrence (E-DR).5 Survival too is reduced,6 even when prognosis would otherwise be relatively good.
One imperative for clinical research has been to find more accurate prognostic cancer biomarkers, especially for high-risk patients. A recent prospective study charts significant progress in E-DR by validating the role of thrombin generation (TG), and its measurement, when using the fully automated, standardised TG analyser, Stago’s ST Genesia.7,8
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.